MC
MYGN icon

Muhlenkamp & Co’s Myriad Genetics MYGN Stock Holding History

Muhlenkamp & Co’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-484,765
Closed -$11.4M – 71
2013
Q3 		$11.4M Buy
484,765
+2,865
+0.6% +$81.4K 2.26% 21
2013
Q2 		$12.9M Buy
+481,900
New +$14M 2.7% 16

Other funds holding MYGN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LCG
Luxor Capital Group New York $1.43B AUM 30.88% 1-Year Est. Return
MCM
Munder Capital Management Birmingham, Michigan $13.4B AUM 18.35% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.28B AUM 23.15% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Muhlenkamp & Co's MYGN Position: Q4 2013 in Review

Muhlenkamp & Co sold out of Myriad Genetics (MYGN) in Q4 2013, closing a stake of 484,765 shares — an estimated $11.4M sold.

Muhlenkamp & Co first reported a position in MYGN in Q2 2013 and held it in 2 quarters. The position peaked at $12.9M in Q2 2013. 270 funds tracked by Wall St. Rank hold MYGN as of Q4 2013.

  • Muhlenkamp & Co reported no remaining Myriad Genetics position as of Q4 2013 after selling out during the quarter.
  • Muhlenkamp & Co sold 484,765 Myriad Genetics shares in Q4 2013, an estimated $11.4M.
  • Muhlenkamp & Co first reported a position in Myriad Genetics in Q2 2013 and held it in 2 quarters.
  • Muhlenkamp & Co's Myriad Genetics position peaked at $12.9M in Q2 2013.
  • 270 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2013.

Based on Muhlenkamp & Co's 13F filing for Q4 2013, filed 14 Feb 2014.